Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2019 Dec 1;4(6):e000599.
doi: 10.1136/esmoopen-2019-000599. eCollection 2019.

Tumour location and efficacy of first-line EGFR inhibitors in KRAS/RAS wild-type metastatic colorectal cancer: retrospective analyses of two phase II randomised Spanish TTD trials

Manuel Benavides  1 , Eduardo Díaz-Rubio  2 , Alfredo Carrato  3 , Albert Abad  4 , Carmen Guillén  5   6 , Pilar Garcia-Alfonso  7 , Silvia Gil  1 , María Teresa Cano  8 , María José Safont  9 , Cristina Gravalos  10 , José Luis Manzano  4 , Antonio Sánchez  11 , Julia Alcaide  12 , Rafael López  13 , Bartomeu Massutí  14 , Javier Sastre  2 , Eva Martínez  15 , Pilar Escudero  16 , Miguel Méndez  17 , Enrique Aranda  7
Affiliations
Clinical Trial

Tumour location and efficacy of first-line EGFR inhibitors in KRAS/RAS wild-type metastatic colorectal cancer: retrospective analyses of two phase II randomised Spanish TTD trials

Manuel Benavides et al. ESMO Open. .

Erratum in

Abstract

Purpose: Metastatic colorectal cancer (mCRC) is a group of distinct diseases, with clinical and molecular differences between right-sided and left-sided tumours driving varying prognosis.

Methods: Patients with KRAS/RAS-wild type (wt) mCRC treated in first line with epidermal growth factor receptor inhibitors (EGFR-Is) (cetuximab or panitumumab) plus oxaliplatin or irinotecan-based chemotherapy from two phase II randomised trials conducted by the Spanish Cooperative for the Treatment of Digestive Tumours group were included in this retrospective study. The main objective was to analyse the prognostic effect of primary tumour location on objective response rate (ORR), progression-free survival (PFS) and overall survival (OS).

Results: Patients with KRAS-wt right-sided tumours (n=52) had significantly lower efficacy as compared with patients with KRAS-wt left-sided tumours (n=209); confirmed ORR (25% vs 47%, respectively; OR 0.4, 95% CI 0.2 to 0.8, p=0.004); and shorter median PFS (7.2 vs 9.9 months; HR 0.6, 95% CI 0.4 to 0.9, p=0.0157) and OS (13.6 vs 27.7 months; HR 0.5, 95% CI 0.3 to 0.7, p<0.0001). Similar results were observed in the RAS-wt populations. The further classification of left-sided tumours as colon or rectum delivered similar survival outcomes, as well as a tendency to diminished ORR in patients with rectum tumours.

Conclusion: We observed significantly improved efficacy outcomes in patients with KRAS/RAS-wt mCRC treated with first-line EGFR-I plus chemotherapy in left-sided primary tumours as compared with right-sided primary tumours.

Trial registration numbers: NCT01161316 and NCT00885885.

Keywords: cetuximab; metastatic colorectal cancer; panitumumab; primary tumour location; sidedness.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Patient disposition for (A) KRAS and (B) RAS wt populations. wt, wild type; mt, mutant type.
Figure 2
Figure 2
Analyses of survival by primary tumour location. (A, B) Kaplan-Meier estimates of the probability of PFS in the KRAS and RAS wt populations, respectively. (C, D) Kaplan-Meier estimates of the probability of OS in the KRAS and RAS wt populations, respectively, in patients with right-sided (blue line) and left-sided (red line) tumours. OS, overall survival; PFS, progression-free survival; wt, wild type.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Tejpar S, Stintzing S, Ciardiello F, et al. . Prognostic and predictive relevance of primary tumor location in patients with RAS wild-type metastatic colorectal cancer: retrospective analyses of the CRYSTAL and FIRE-3 trials. JAMA Oncol 2017;3:194–201. 10.1001/jamaoncol.2016.3797 - DOI - PMC - PubMed
    1. Brulé SY, Jonker DJ, Karapetis CS, et al. . Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17. Eur J Cancer 2015;51:1405–14. 10.1016/j.ejca.2015.03.015 - DOI - PubMed
    1. Loupakis F, Yang D, Yau L, et al. . Primary tumor location as a prognostic factor in metastatic colorectal cancer. J Natl Cancer Inst 2015;107:dju427 10.1093/jnci/dju427 - DOI - PMC - PubMed
    1. von Einem JC, Heinemann V, von Weikersthal LF, et al. . Left-Sided primary tumors are associated with favorable prognosis in patients with KRAS codon 12/13 wild-type metastatic colorectal cancer treated with cetuximab plus chemotherapy: an analysis of the AIO KRK-0104 trial. J Cancer Res Clin Oncol 2014;140:1607–14. 10.1007/s00432-014-1678-3 - DOI - PMC - PubMed
    1. Moretto R, Cremolini C, Rossini D, et al. . Location of primary tumor and benefit from anti-epidermal growth factor receptor monoclonal antibodies in patients with Ras and BRAF wild-type metastatic colorectal cancer. Oncologist 2016;21:988–94. 10.1634/theoncologist.2016-0084 - DOI - PMC - PubMed

Publication types

MeSH terms

Associated data